T
Tommy Fornander
Researcher at Karolinska Institutet
Publications - 145
Citations - 9997
Tommy Fornander is an academic researcher from Karolinska Institutet. The author has contributed to research in topics: Breast cancer & Tamoxifen. The author has an hindex of 49, co-authored 137 publications receiving 9254 citations. Previous affiliations of Tommy Fornander include Karolinska University Hospital.
Papers
More filters
Journal ArticleDOI
Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers
Tommy Fornander,Björn Cedermark,Anders Mattsson,Lambert Skoog,Tolle Theve,Jutta Askergren,LabsE. Rutqvist,Ulla Glas,Claes Silfverswärd,Anders Somell,Nils Wilking,Marie-Louise Hjalmar +11 more
TL;DR: The frequency of new primary cancers was studied in 1846 postmenopausal patients included in a randomised trial of tamoxifen as an adjunct to primary surgery for early breast cancer and the increase in endometrial cancers was most pronounced in those treated for over 2 years.
Journal ArticleDOI
Adjuvant docetaxel for node-positive breast cancer.
Miguel Martin,Tadeusz Pienkowski,John R. Mackey,M. Pawlicki,Jean-Paul Guastalla,Charles Weaver,Eva Tomiak,T. Al-Tweigeri,Linnea Chap,Eva Juhos,Raymond Guevin,Anthony Howell,Tommy Fornander,John D. Hainsworth,Robert E. Coleman,Jefferson Vinholes,Manuel Modiano,Tamás Pintér,Shou C. Tang,Bruce Colwell,Catherine Prady,Louise Provencher,David Walde,Álvaro Rodríguez-Lescure,Judith Hugh,Camille Loret,Matthieu Rupin,Sandra Blitz,Philip Jacobs,Michael Murawsky,Alessandro Riva,Charles L. Vogel +31 more
TL;DR: Adjuvant chemotherapy with TAC, as compared with FAC, significantly improves the rates of disease-free and overall survival among women with operable node-positive breast cancer.
Proceedings ArticleDOI
Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study.
DJ Slamon,Wolfgang Eiermann,Nicholas J. Robert,Tadeusz Pienkowski,Miguel Martín,J. Rolski,Arlene Chan,John R. Mackey,MC Liu,Tamás Pintér,V. Valero,Carla I. Falkson,Tommy Fornander,TA Shiftan,S. Olsen,Marc Buyse,T. Kiskartalyi,V. Landreau,V. Wilson,Michael F. Press,John Crown +20 more
TL;DR: The results of this trial help define the role of trastuzumab in the breast cancer HER2-positive adjuvant setting, as well as the risks/benefits of adjUvant trastzumab within the context of overall safety including cardiac toxicity.
Journal ArticleDOI
Adjuvant Tamoxifen Therapy for Early Stage Breast Cancer and Second Primary Malignancies
Lars Erik Rutqvist,Hemming Johansson,Tongplaew Signomklao,Ulla Johansson,Tommy Fornander,Nils Wilking +5 more
TL;DR: The endometrium and gastrointestinal organs may be target sites for tamoxifen-induced carcinogenesis in humans and the increased incidence of colorectal and stomach cancers reported here should be regarded as tentative until supported by long-term data from a larger number of tamoxIFen trials.
Journal ArticleDOI
Cardiovascular mortality in a randomized trial of adjuvant radiation therapy versus surgery alone in primary breast cancer.
TL;DR: In this paper, the authors presented an analysis of long-term survival among 960 patients with primary breast cancer included in a randomized trial of pre- or postoperative radiation therapy (45 Gy/5 weeks) versus surgery alone.